Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2013, Pages 244-249

  Misaka, Shingen ^a,b   Kawabe, Keisuke ^a   Onoue, Satomi ^a   Pablowerba, José ^c   Giroli, Monica ^c   Tamaki, Sekihiro ^a   Kan, Toshiyuki ^d   Kimura, Junko ^b   Watanabe, Hiroshi ^e   Yamada, Shizuo ^a  

^a Department of Pharmacokinetics and Pharmacodynamics ^*  (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d UNIVERSITY OF SHIZUOKA   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

( ) epigallocatechin 3 gallate; Catechins; Cytochrome P450; Green tea extract

Indexed keywords

AMFEBUTAMONE; AMODIAQUINE; CATECHIN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DRUG METABOLITE; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; MEPHENYTOIN; MIDAZOLAM; SUNPHENONBG3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEETHYLATION; DEMETHYLATION; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INTESTINE MICROSOME; LIVER MICROSOME; MALE; MICROSOME;

EID: 84879391245     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-101     Document Type: Article

References (35)

1. Paine, M. F. and Oberlies, N. H.: Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin. Drug Metab. Toxicol., 3: 67-80 (2007).
2. Custodio, J. M., Wu, C. Y. and Benet, L. Z.: Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev., 60: 717-733 (2008).
3. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J. and Krahenbuhl, S.: Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 58: 20-28 (1995).
4. Edwards, D. J., Bellevue, F. H., 3rd and Woster, P. M.: Identification of 6A,7A-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos., 24: 1287-1290 (1996).
5. Graham, H. N.: Green tea composition, consumption, and polyphenol chemistry. Prev. Med., 21: 334-350 (1992).
6. Yang, C. S., Wang, X., Lu, G. and Picinich, S. C.: Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer, 9: 429-439 (2009).
7. Matsumoto, K., Yamada, H., Takuma, N., Niino, H. and Sagesaka, Y. M.: Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. BMC Complement. Altern. Med., 11: 15 (2011).
8. Khan, N. and Mukhtar, H.: Tea polyphenols for health promotion. Life Sci., 81: 519-533 (2007).
9. Feng, W. Y.: Metabolism of green tea catechins: an overview. Curr. Drug Metab., 7: 755-809 (2006).
10. Muto, S., Fujita, K., Yamazaki, Y. and Kamataki, T.: Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat. Res., 479: 197-206 (2001).
11. Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I., Nakamura, H., Nakasa, H., Ida, M., Nakamura, H., Kimura, N., Kimura, M., Hasegawa, A., Kusu, F., Ohmori, S., Nakazawa, K. and Kitada, M.: Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab. Pharmacokinet., 19: 280-289 (2004).
12. Donovan, J. L., Chavin, K. D., Devane, C. L., Taylor, R. M., Wang, J. S., Ruan, Y. and Markowitz, J. S.: Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab. Dispos., 32: 906-908 (2004).
13. Yasui, N., Kondo, T., Furukori, H., Kaneko, S., Ohkubo, T., Uno, T., Osanai, T., Sugawara, K. and Otani, K.: Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berlin), 150: 185-190 (2000).
14. Chow, H. H., Hakim, I. A., Vining, D. R., Crowell, J. A., Cordova, C. A., Chew, W. M., Xu, M. J., Hsu, C. H., Ranger-Moore, J. and Alberts, D. S.: Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol. Biomarkers Prev., 15: 2473-2476 (2006).
15. Werba, J. P., Giroli, M., Cavalca, V., Nava, M. C., Tremoli, E. and Dal Bo, L.: The effect of green tea on simvastatin tolerability. Ann. Intern. Med., 149: 286-287 (2008).
16. Prueksaritanont, T., Ma, B. and Yu, N.: The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol., 56: 120-124 (2003).
17. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M. and Lindley, C. M.: Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos., 28: 1222-1230 (2000).
18. Li, X. Q., Bjorkman, A., Andersson, T. B., Gustafsson, L. L. and Masimirembwa, C. M.: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol., 59: 429-442 (2003).
19. Walsky, R. L. and Obach, R. S.: Validated assays for human cytochrome P450 activities. Drug Metab. Dispos., 32: 647-660 (2004).
20. Qiu, F., Zhang, R., Sun, J., Jiye, A., Hao, H., Peng, Y., Ai, H. and Wang, G.: Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos., 36: 1308-1314 (2008).
21. Quintieri, L., Palatini, P., Nassi, A., Ruzza, P. and Floreani, M.: Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol., 75: 1426-1437 (2008).
22. Paine, M. F., Criss, A. B. and Watkins, P. B.: Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab. Dispos., 32: 1146-1153 (2004).
23. Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E. and Zeldin, D. C.: The human intestinal cytochrome P450 "pie. " Drug Metab. Dispos., 34: 880-886 (2006).
24. Li, X. Q., Bjorkman, A., Andersson, T. B., Ridderstrom, M. and Masimirembwa, C. M.: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther., 300: 399-407 (2002).
25. Lau, A. J. and Chang, T. K.: Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab. Dispos., 37: 1931-1937 (2009).
26. Tachibana, T., Kato, M., Watanabe, T., Mitsui, T. and Sugiyama, Y.: Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica, 39: 430-443 (2009).
27. Imai, K., Suga, K. and Nakachi, K.: Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med., 26: 769-775 (1997).
28. 1)-epigallocatechin, into human plasma. Biosci. Biotechnol. Biochem., 61: 1981-1985 (1997).
29. Turpeinen, M., Raunio, H. and Pelkonen, O.: The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab., 7: 705-714 (2006).
30. Wang, H. and Tompkins, L. M.: CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab., 9: 598-610 (2008).
31. Totah, R. A. and Rettie, A. E.: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 77: 341-352 (2005).
32. Václavíková, R., Horsky, S., Simek, P. and Gut, I.: Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch. Pharmacol., 368: 200-209 (2003).
33. Guengerich, F. P.: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39: 1-17 (1999).
34. Ingelman-Sundberg, M.: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J., 5: 6-13 (2005).
35. Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C. and Lithgow, J.: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol., 69: 222-230 (2010).